MediLink

MediLink, a company located in Suzhou, is an innovative firm focusing on the development of Antibody–Drug Conjugates (ADC) and related technologies and drugs, founded in 2020. ADC drugs combine the powerful killing effect of traditional small-molecule chemotherapy with the tumor-targeting properties of antibody drugs. With breakthroughs in key technologies, multiple ADC drugs have been successively launched in the past two years. The entire ADC industry has witnessed significant developments, and new technologies represented by ADC are expected to lead the next decade of new drug research and development, potentially giving rise to more blockbuster drugs and addressing substantial unmet clinical needs. MediLink was established by a team of talents with extensive domestic and international experience in innovative ADC drug development and management, corporate management, and capital operations. The company is dedicated to developing the latest generation of proprietary ADC technology to discover drugs with an improved therapeutic window; simultaneously, it promotes iterative updates of its technology, building a diversified ADC technology platform to maintain technological leadership and develop differentiated products, extending the product lifecycle. Additionally, the company will continue to carry out product development and cooperation on an international scale.